Acne Supplements: What Zinc, Probiotics, and Omega-3s Can Do

Most acne supplements have a marketing problem before they have a science problem

Zinc can reduce acne lesions in some trials, but only at high doses that often upset the stomach. High-dose vitamin A failed in a placebo-controlled trial and carries serious safety risks. Probiotics and omega-3s have credible reasons to be studied, yet neither has enough reliable clinical detail to prescribe as an acne treatment.

That is the useful reading of a 2023 JAMA Dermatology systematic review. It included 42 randomized controlled trials, with 3,346 participants, of oral nutraceuticals for acne. The review covered zinc, vitamins, probiotics, omega-3 fatty acids, and other products. Its larger finding should temper every enthusiastic label claim: 64.3% of the trials were poor quality, 26.2% were fair quality, and only about 9.5%—roughly four studies—met good-quality criteria.

A randomized trial can answer a useful question only if it is designed and reported well. In this literature, small samples, short follow-up, inconsistent acne measures, and weak blinding were common. Positive results therefore count as leads, not licenses to call a capsule a replacement for prescription acne care.

The evidence supports a hierarchy, not a shopping cart: zinc has the most clinical trial data; probiotics and fatty-acid biology merit further study; high-dose vitamin A belongs off the list.

Zinc has the most evidence, with important strings attached

Zinc appeared in 15 of the 42 trials, making it the best-studied oral nutraceutical in the review. That is a relative distinction, not a declaration of victory. No zinc trial received a good-quality rating, and results differed by dose and trial.

One 12-week trial in 35 participants found that zinc sulfate at 440 mg per day did not beat placebo; the result was not statistically significant (P>0.05). Several fair-quality trials using higher regimens—about 600 mg per day of zinc sulfate or 200 mg per day of zinc gluconate—reported significant improvements in lesion counts or composite acne scores. The review describes those results as heterogeneous, so they do not establish a predictable percentage improvement for a given person.

A direct comparison found that 600 mg per day of zinc performed approximately as well as oxytetracycline for lesion reduction, without statistically significant superiority for either treatment. That makes zinc a possible adjunct or an option worth discussing when standard oral antibiotics are unsuitable. It does not show that zinc works better than antibiotics, nor that it replaces topical or oral retinoids for moderate-to-severe acne.

The doses associated with benefit also caused nausea, vomiting, and abdominal pain at clinically meaningful rates. The practical question is not simply whether zinc has a signal; it is whether a person can tolerate the regimen that produced it. Standard over-the-counter dosing cannot borrow credibility from higher-dose trials.

Vitamin B5 has one encouraging trial; vitamin A has a clear stop sign

Pantothenic acid, commonly sold as vitamin B5, has a narrow evidence base. In one fair-quality, placebo-controlled 12-week trial of 41 participants, 2.2 g per day significantly reduced total facial lesions. Pantothenic acid helps form coenzyme A, which participates in lipid metabolism, but a plausible pathway does not replicate a trial. One small study is enough to justify replication, not a confident recommendation.

High-dose vitamin A is different because the benefit-risk calculation is already unfavorable. In a 12-week placebo-controlled trial, 150,000 IU per day produced no clinician-assessed benefit. At acne-therapeutic doses, vitamin A also carries documented teratogenic and neuropsychiatric risks. Calling it a "natural isotretinoin alternative" confuses a nutrient with a prescription drug and skips the safety data. People who could become pregnant should not experiment with high-dose vitamin A for acne.

Omega-3 biology is interesting, but genetics cannot prescribe a dose

The lipid-acne connection has gained a stronger kind of evidence than a diet questionnaire. Liu and colleagues' 2025 Mendelian-randomization study used inherited genetic variants as instrumental variables to examine whether circulating lipid metabolites lie upstream of acne risk. The analysis identified specific lipid metabolite species, including fatty-acid subclasses, as causally related to acne susceptibility.

Mendelian randomization is more resistant than conventional observational research to confounding by diet, body weight, health behavior, and other correlated factors. It can support causal inference about the biological pathway. It cannot tell a reader that taking a particular fish-oil product at a particular dose will reduce lesions. The publication's abstract does not provide the full effect estimates, confidence intervals, or the trial data needed to make that translation.

A 2025 analysis of unsaturated fatty acids also reported clinical and genetic evidence connecting fatty acids with acne, but the available publication record contains a mismatch that prevents reliable use of its specific statistics. The defensible conclusion is narrower: lipid metabolism deserves better acne trials, including trials that specify EPA and DHA doses, comparators, lesion-count endpoints, and follow-up. Genetic plausibility is not an acne treatment plan.

Probiotics may help, but "probiotic" is not a strain

Probiotics are a legitimate research area, not a magic word. A 2026 GRADE systematic review and meta-analysis evaluated randomized trials of Lactobacillus-based microbiome therapy for acne vulgaris. GRADE is a framework for rating certainty in evidence; it does not, by itself, make every included result conclusive.

The rationale is biologically credible. A 2025 review of probiotics in dermatology describes possible effects on inflammatory signaling, the gut-skin axis, the sebaceous microbiome, and Cutibacterium acnes virulence. Oral and topical products may work through different routes. More importantly, products contain different organisms, formulations, and doses. A result for one Lactobacillus strain does not validate every supplement with "probiotic" on the bottle.

The currently available clinical reporting does not establish a strain-specific dose, duration, or head-to-head comparison with standard acne therapies. A probiotic may be a reasonable low-risk add-on for some people, but it remains an adjunct with unsettled clinical details.

A ketogenic diet is an intervention, not a supplement

A very-low-calorie ketogenic diet deserves separate treatment because it asks much more of a person than swallowing a pill. In a 2024 study of 31 women aged 18 to 30 with treatment-naive moderate acne and grade I obesity, investigators evaluated a 45-day active phase of the diet. The proposed rationale is that ketosis and weight loss may reduce inflammatory and oxidative stress pathways relevant to acne.

That population matters. The findings cannot automatically extend to people without obesity, to adolescents, or to people already using acne treatment. The study supports further research in people with metabolic overlap and acne; it does not make a very-low-calorie ketogenic diet a first-line acne intervention. Restrictive diets also carry adherence and health considerations that require more care than an influencer's meal-prep montage.

What to do with this evidence

For mild acne, a person who wants to try a supplement should set a modest goal and avoid replacing established treatment. High-dose zinc has the most repeated randomized-trial support, but its evidence is fair to poor in quality, its response is variable, and gastrointestinal effects limit its appeal. Pantothenic acid has one small fair-quality positive trial. Lactobacillus-based therapies and omega-3-related lipid biology are worth watching, not overselling.

For moderate or severe acne, scarring, sudden adult-onset acne, or acne affecting mood, clinician-guided treatment has a stronger foundation than nutraceuticals. The JAMA Dermatology review found no oral nutraceutical that had proved superior to standard antibiotics or retinoids in adequately powered, good-quality trials. High-dose vitamin A has no demonstrated clinical benefit here and a safety profile that rules it out for general use.

The honest verdict is unglamorous but useful: acne supplements can be low-certainty additions, not primary treatment. Zinc has a real but limited clinical signal. Omega-3s and probiotics have rational research paths. The rest of the shelf still needs better trials.